BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30708041)

  • 21. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
    Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
    Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.
    Zacharias NM; McCullough C; Shanmugavelandy S; Lee J; Lee Y; Dutta P; McHenry J; Nguyen L; Norton W; Jones LW; Bhattacharya PK
    Sci Rep; 2017 Nov; 7(1):16159. PubMed ID: 29170516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells.
    Fu YM; Zhang H; Ding M; Li YQ; Fu X; Yu ZX; Meadows GG
    J Cell Physiol; 2006 Nov; 209(2):522-34. PubMed ID: 16897757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.
    Dueregger A; Schöpf B; Eder T; Höfer J; Gnaiger E; Aufinger A; Kenner L; Perktold B; Ramoner R; Klocker H; Eder IE
    PLoS One; 2015; 10(8):e0135704. PubMed ID: 26285134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
    Mertan F; Turkbey B
    Pharmacol Res; 2016 Dec; 114():163-165. PubMed ID: 27777131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Metabolic Phenotype of Prostate Cancer.
    Eidelman E; Twum-Ampofo J; Ansari J; Siddiqui MM
    Front Oncol; 2017; 7():131. PubMed ID: 28674679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
    Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
    Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroid biosynthesis and prostate cancer.
    Sharifi N; Auchus RJ
    Steroids; 2012 Jun; 77(7):719-26. PubMed ID: 22503713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the Response of Tumours Dependent on the Dietary Input of Some Amino Acids or Ratios among Essential and Non-Essential Amino Acids? All That Glitters Is Not Gold.
    Dioguardi FS; Flati V; Corsetti G; Pasini E; Romano C
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect.
    Sun L; Suo C; Li ST; Zhang H; Gao P
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):51-66. PubMed ID: 29959989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells.
    Fu YM; Yu ZX; Li YQ; Ge X; Sanchez PJ; Fu X; Meadows GG
    Nutr Cancer; 2003; 45(1):60-73. PubMed ID: 12791506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Personalized medicine and prostate cancer. The reality of change].
    Carballido Rodríguez JA; Martínez-Salamanca JI
    Arch Esp Urol; 2015 Apr; 68(3):391-400. PubMed ID: 25948808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection.
    di Salvo ML; Contestabile R; Paiardini A; Maras B
    Med Hypotheses; 2013 May; 80(5):633-6. PubMed ID: 23474074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications.
    Butler LM; Centenera MM; Swinnen JV
    Endocr Relat Cancer; 2016 May; 23(5):R219-27. PubMed ID: 27130044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
    Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Robles-Fernandez I; Martinez-Herrera J; Garcia-Rodriguez G; Pascual-Geler M; Cozar JM; Lorente JA
    Mol Diagn Ther; 2017 Apr; 21(2):167-178. PubMed ID: 27995550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression.
    Kratochvilova M; Raudenska M; Heger Z; Richtera L; Cernei N; Adam V; Babula P; Novakova M; Masarik M; Gumulec J
    Prostate; 2017 May; 77(6):604-616. PubMed ID: 28101932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organ-Specific Cancer Metabolism and Its Potential for Therapy.
    Elia I; Schmieder R; Christen S; Fendt SM
    Handb Exp Pharmacol; 2016; 233():321-53. PubMed ID: 25912014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.
    Li Z; Zhang H
    Cell Mol Life Sci; 2016 Jan; 73(2):377-92. PubMed ID: 26499846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer.
    Sun H; Zhang AH; Liu SB; Qiu S; Li XN; Zhang TL; Liu L; Wang XJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():143-151. PubMed ID: 30391728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
    Gasparrini S; Cimadamore A; Mazzucchelli R; Scarpelli M; Massari F; Raspollini MR; Galosi AB; Lopez-Beltran A; Cheng L; Montironi R
    Expert Rev Mol Diagn; 2017 Aug; 17(8):781-789. PubMed ID: 28598696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.